FDA approves Niktimvo for chronic graft-versus-host disease
Drug Discovery World
AUGUST 20, 2024
The US Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD). ORR was 75% in the 79 patients treated with the recommended dosage. The median time to first response was 1.5
Let's personalize your content